News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Sangamo Therapeutics, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Technique To Fix DNA Flaws Is Tested
October 19, 2005
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Business
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
April 28, 2022
·
1 min read
Biotech Bay
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Apr 21, 2022
April 21, 2022
·
1 min read
Drug Development
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
March 29, 2022
·
6 min read
Biotech Bay
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Feb 28, 2022
February 28, 2022
·
1 min read
Business
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
February 24, 2022
·
16 min read
Business
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
February 17, 2022
·
1 min read
Drug Development
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
February 7, 2022
·
8 min read
Business
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
January 6, 2022
·
7 min read
Biotech Bay
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
January 4, 2022
·
1 min read
Drug Development
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
December 12, 2021
·
13 min read
